CidaraLogo (1).jpg
Cidara Provides Corporate Update and Reports Second Quarter 2019 Financial Results
August 08, 2019 16:07 ET | Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported financial...
CidaraLogo (1).jpg
Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
August 07, 2019 07:30 ET | Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin
July 29, 2019 07:00 ET | Cidara Therapeutics, Inc.
Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections ...
CidaraLogo (1).jpg
Cidara Provides Corporate Update and Reports First Quarter 2019 Financial Results
May 09, 2019 16:13 ET | Cidara Therapeutics, Inc.
SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
CidaraLogo (1).jpg
Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
April 03, 2019 16:04 ET | Cidara Therapeutics, Inc.
SAN DIEGO, April 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
CidaraLogo (1).jpg
Cidara Therapeutics Announces Offering of Common Stock and Warrants
May 21, 2018 07:30 ET | Cidara Therapeutics, Inc.
SAN DIEGO, May 21, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has...
CidaraLogo (1).jpg
Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Common Stock
October 19, 2017 09:00 ET | Cidara Therapeutics, Inc.
SAN DIEGO, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the pricing...
CidaraLogo (1).jpg
Cidara Provides Corporate Update and Reports Second Quarter 2017 Financial Results
August 09, 2017 16:31 ET | Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
CidaraLogo (1).jpg
Cidara Provides Corporate Update and Reports First Quarter 2017 Financial Results
May 10, 2017 17:06 ET | Cidara Therapeutics, Inc.
SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
CidaraLogo (1).jpg
Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC
February 21, 2017 07:30 ET | Cidara Therapeutics, Inc.
Further Development of CD101 Topical for VVC to be discontinued CD101 IV development program in candidemia and invasive candidiasis (including Phase 2 STRIVE trial) continuing and remains on track ...